Laboratory and clinical studies on cefpirome

Yoshio Sawae, Toshiyuki Ishimaru, Koji Takagi, Nobuyuki Shimono

Research output: Contribution to journalArticle

Abstract

We performed laboratory and clinical studies on cefpirome (CPR), a new injectable cephem antibiotic, with the following results. 1. Antibacterial activity The MICs of CPR against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 µg/ml for Staphylococcus aureus, 25 µg/ml for Enterococcus faecalis, 0.10 µg/ml for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes and Proteus mirabilis, 0.39 µg/ml for Serratia marcescens, 0.78 µg/ml for Enterobacter cloacae and Proteus vulgaris, 1.56 µg/ml for Citrobacter spp. and 50 µg/ml for Pseudomonas aeruginosa. It was also found that, compared with the control drugs, cefotaxime, ceftazidime and cefoperazone, CPR showed superior activity against many kinds of bacteria. 2. Clinical results A total of 11 patients (5 with pneumonia. 2 with acute bronchitis. 1 with chronic bronchitis, 1 with pyelonephritis and 1 with fever of unknown origin) were treated with CPR at a daily dose of 2 g for 5-20 days. Clinical response was excellent in 1 patient, good in 7. fair in 2 and poor in 1. No side-effects were observed, but eosinophilia was noted in three patients. From the above results, we consider that CPR is one of the most useful antibiotics for the treatment of infectious diseases.

Original languageEnglish
Pages (from-to)192-197
Number of pages6
JournalCHEMOTHERAPY
Volume39
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

cefpirome
Citrobacter
Proteus vulgaris
Anti-Bacterial Agents
Enterobacter aerogenes
Fever of Unknown Origin
Cefoperazone
Enterobacter cloacae
Proteus mirabilis
Serratia marcescens
Ceftazidime
Cefotaxime
Bronchitis
Enterococcus faecalis
Drug and Narcotic Control
Pyelonephritis
Chronic Bronchitis
Klebsiella pneumoniae
Eosinophilia
Cell Size

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Laboratory and clinical studies on cefpirome. / Sawae, Yoshio; Ishimaru, Toshiyuki; Takagi, Koji; Shimono, Nobuyuki.

In: CHEMOTHERAPY, Vol. 39, 01.01.1991, p. 192-197.

Research output: Contribution to journalArticle

Sawae, Yoshio ; Ishimaru, Toshiyuki ; Takagi, Koji ; Shimono, Nobuyuki. / Laboratory and clinical studies on cefpirome. In: CHEMOTHERAPY. 1991 ; Vol. 39. pp. 192-197.
@article{7b7eafd0dacd496e9b12df33e34333c4,
title = "Laboratory and clinical studies on cefpirome",
abstract = "We performed laboratory and clinical studies on cefpirome (CPR), a new injectable cephem antibiotic, with the following results. 1. Antibacterial activity The MICs of CPR against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 µg/ml for Staphylococcus aureus, 25 µg/ml for Enterococcus faecalis, 0.10 µg/ml for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes and Proteus mirabilis, 0.39 µg/ml for Serratia marcescens, 0.78 µg/ml for Enterobacter cloacae and Proteus vulgaris, 1.56 µg/ml for Citrobacter spp. and 50 µg/ml for Pseudomonas aeruginosa. It was also found that, compared with the control drugs, cefotaxime, ceftazidime and cefoperazone, CPR showed superior activity against many kinds of bacteria. 2. Clinical results A total of 11 patients (5 with pneumonia. 2 with acute bronchitis. 1 with chronic bronchitis, 1 with pyelonephritis and 1 with fever of unknown origin) were treated with CPR at a daily dose of 2 g for 5-20 days. Clinical response was excellent in 1 patient, good in 7. fair in 2 and poor in 1. No side-effects were observed, but eosinophilia was noted in three patients. From the above results, we consider that CPR is one of the most useful antibiotics for the treatment of infectious diseases.",
author = "Yoshio Sawae and Toshiyuki Ishimaru and Koji Takagi and Nobuyuki Shimono",
year = "1991",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.39.Supplement1_192",
language = "English",
volume = "39",
pages = "192--197",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Laboratory and clinical studies on cefpirome

AU - Sawae, Yoshio

AU - Ishimaru, Toshiyuki

AU - Takagi, Koji

AU - Shimono, Nobuyuki

PY - 1991/1/1

Y1 - 1991/1/1

N2 - We performed laboratory and clinical studies on cefpirome (CPR), a new injectable cephem antibiotic, with the following results. 1. Antibacterial activity The MICs of CPR against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 µg/ml for Staphylococcus aureus, 25 µg/ml for Enterococcus faecalis, 0.10 µg/ml for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes and Proteus mirabilis, 0.39 µg/ml for Serratia marcescens, 0.78 µg/ml for Enterobacter cloacae and Proteus vulgaris, 1.56 µg/ml for Citrobacter spp. and 50 µg/ml for Pseudomonas aeruginosa. It was also found that, compared with the control drugs, cefotaxime, ceftazidime and cefoperazone, CPR showed superior activity against many kinds of bacteria. 2. Clinical results A total of 11 patients (5 with pneumonia. 2 with acute bronchitis. 1 with chronic bronchitis, 1 with pyelonephritis and 1 with fever of unknown origin) were treated with CPR at a daily dose of 2 g for 5-20 days. Clinical response was excellent in 1 patient, good in 7. fair in 2 and poor in 1. No side-effects were observed, but eosinophilia was noted in three patients. From the above results, we consider that CPR is one of the most useful antibiotics for the treatment of infectious diseases.

AB - We performed laboratory and clinical studies on cefpirome (CPR), a new injectable cephem antibiotic, with the following results. 1. Antibacterial activity The MICs of CPR against various clinical isolates were determined with an inoculum size of 106 cells/ml. The MIC80 was 3.13 µg/ml for Staphylococcus aureus, 25 µg/ml for Enterococcus faecalis, 0.10 µg/ml for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes and Proteus mirabilis, 0.39 µg/ml for Serratia marcescens, 0.78 µg/ml for Enterobacter cloacae and Proteus vulgaris, 1.56 µg/ml for Citrobacter spp. and 50 µg/ml for Pseudomonas aeruginosa. It was also found that, compared with the control drugs, cefotaxime, ceftazidime and cefoperazone, CPR showed superior activity against many kinds of bacteria. 2. Clinical results A total of 11 patients (5 with pneumonia. 2 with acute bronchitis. 1 with chronic bronchitis, 1 with pyelonephritis and 1 with fever of unknown origin) were treated with CPR at a daily dose of 2 g for 5-20 days. Clinical response was excellent in 1 patient, good in 7. fair in 2 and poor in 1. No side-effects were observed, but eosinophilia was noted in three patients. From the above results, we consider that CPR is one of the most useful antibiotics for the treatment of infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=0026081705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026081705&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.39.Supplement1_192

DO - 10.11250/chemotherapy1953.39.Supplement1_192

M3 - Article

AN - SCOPUS:0026081705

VL - 39

SP - 192

EP - 197

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -